NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Latest Information Update: 10 Jun 2024
At a glance
- Drugs NP G2 044 (Primary) ; Programmed cell death 1 receptor antagonists (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novita Pharmaceuticals
- 04 Jun 2024 Results of safety of NP-G2-044 administered as both monotherapy (MT) and in combination (CT), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 09 Nov 2023 Planned End Date changed from 1 Jun 2024 to 1 Sep 2024.
- 09 Nov 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Sep 2024.